sipuleucel t popular tagged News at allvoices.com

sipuleucel t news

News tagged with “sipuleucel t”. Found: 233 tagged news reports.
 

Your Search Returned 233 tagged news reports

 
Related Tags:

Amsterdam :: Netherlands | 6 months ago

Credibility Credibility of 5

Provenge is an autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T. The product had received marketing authorization from the European Commission (EC) in September 2013 for the treatment of asymptomatic or

Tags:

Aua :: American Samoa | 11 months ago

Credibility Credibility of 5

Net product revenue for the quarter was $67.6 million compared to $82.0 million for the quarter ended March 31, 2012, down 17.6% year over year. Net loss in the first quarter of 2013 was $72.0 million, or $0.48 per share, compared to a net loss of $

Tags:

Buy :: Russia | 1 year ago

Credibility Credibility of 5

Buy & 1 to Sell After Earnings on Monday Brian is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited. Monday was a somewhat slow day in terms of companies reporting earnings;

Tags:

Alexandria :: VA :: USA | over 1 year ago

Credibility Credibility of 5

Bernstein upgraded the stock from "market-perform" to "outperform." Even better, Berstein singled out the drug company as potentially one of the top stocks of 2013.  What it means Any good news is welcome for long-suffering Dendreon. The stock

Tags:

Newark :: NJ :: USA | over 1 year ago

Credibility Credibility of 5

Things to Watch at Dendreon Watch stocks you care about The single, easiest way to keep track of all the stocks that matter.....After its subsequent approval, Provenge missed sales guidance, causing Dendreon's shares to plummet near where there were

Tags:

Bridgewater :: MA :: USA | over 1 year ago

Credibility Credibility of 5

The Dendreon saga has been the proverbial rollercoaster ride. Hailed several years ago as a breakthrough immunotherapy for prostate cancer, its Provenge vaccine seemed likely to win FDA approval five years ago until an unusual turn of events prompted

Tags:

Alexandria :: VA :: USA | over 1 year ago

Credibility Credibility of 5

Dendreon 's press releases over the past year are seemingly filled with nothing but bad news. Investors suffered another gut punch today, as shares plummeted 23% amid declining Provenge sales -- but also in the face of a significant operational shake-

Tags:

Alexandria :: VA :: USA | over 1 year ago

Credibility Credibility of 5

The company is closing the New Jersey plant that manufactures its prostate cancer treatment Provenge. In doing so, the biotech basically said, "We don't think there's any way we'll be able to hit our previous goals any time in the medium term." The

Tags:

Seattle :: WA :: USA | over 1 year ago

Credibility Credibility of 5

Dendreon Corp. unveiled restructuring plans that include cutting more than 600 additional jobs, as the biotechnology company continues to lose money due to slow sales of its prostate-cancer treatment. The latest layoffs represent about 41% of the

Tags:

Alexandria :: VA :: USA | over 1 year ago

Credibility Credibility of 5

Since we looked at Dendreon last year , the company has kept its four-point score. Despite continuing sales success, the biotech hasn't managed to convert revenue to profits, and that's why shares have tumbled more than 80% over the past year.

Tags:



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.